(Albany, New York) – 2nd Sep 2026 – The market dynamics for Radiation-Induced Oral Mucositis in Prostate Cancer are witnessing steady growth driven by the rising incidence of prostate cancer, increasing utilization of radiotherapy, growing adoption of advanced radiation techniques such as IMRT and SBRT, and increasing awareness of gastrointestinal and genitourinary toxicities associated with pelvic radiation. Additionally, the growing need for effective supportive care, preventive strategies, and cost-effective therapies, along with the development of emerging treatment approaches such as LP-10, is expected to further propel the Radiation-Induced Oral Mucositis in Prostate Cancer market during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Radiation Induced Oral Mucositis in Prostate Cancer Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Radiation-Induced Oral Mucositis in Prostate Cancer, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Radiation-Induced Oral Mucositis in Prostate Cancer Market

• The market size for Radiation-Induced Oral Mucositis in Prostate Cancer in the leading markets is expected to grow significantly by 2036.

• The 7MM Radiation-Induced Oral Mucositis in Prostate Cancer market was approximately USD 30 million in 2025 and is projected to increase to nearly USD 75 million by 2036, reflecting a 9% CAGR during 2026–2036.

• According to DelveInsight’s estimates, the total prevalent cases of prostate cancer in the 7MM were approximately 7.7 million in 2025, and these cases are expected to increase during the forecast period.

• In 2025, radiotherapy utilization in the United States was highest among patients with localized prostate cancer, accounting for approximately 270,000 cases, followed by nmCSPC/nmHSPC, with approximately 254,000 cases.

• In the United States, IMRT was the most widely adopted and advanced form of radiotherapy in prostate cancer, accounting for approximately 390,000 treated cases in 2025.

• The increasing adoption of IMRT, driven by its favorable toxicity profile and ability to deliver higher, more conformal doses, is expected to expand the radiotherapy-treated population and consequently increase the pool of patients at risk for radiation-related pelvic toxicities.

• In 2025, the United Kingdom accounted for approximately 35% of the combined Radiation-Induced Oral Mucositis in Prostate Cancer market across EU4 and the UK, reflecting its notably higher disease prevalence rate.

• In 2025, the United States accounted for the highest market size among the 7MM, followed by Japan.

• In 2025, treatment spending across the 7MM was largely concentrated on suppository/enema, accounting for approximately USD 15 million, followed by intravenous fluid, at approximately USD 6 million.

• There are currently no approved pharmacologic therapies specifically for radiation-induced mucositis in prostate cancer, with current management largely relying on supportive care, topical agents, symptomatic medications, and endoscopic or procedural interventions.

• Leading Radiation-Induced Oral Mucositis in Prostate Cancer companies, including Lipella Pharmaceuticals and others, are developing emerging treatment approaches expected to address significant unmet needs in the treatment landscape.

• Promising therapies and emerging approaches include LP-10, 3-D Matrix, HT-02, RDD-2007, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/radiation-induced-oral-mucositis-in-prostate-cancer-market

Key Factors Driving the Radiation-Induced Oral Mucositis in Prostate Cancer MarketRising Incidence of Prostate Cancer and Radiotherapy Utilization

The increasing incidence of prostate cancer across key geographies, together with the widespread use of radiotherapy for prostate cancer management, is expanding the population exposed to pelvic irradiation. Radiotherapy utilization is particularly high in localized prostate cancer, creating a substantial and growing survivorship population at risk for radiation-related mucosal and organ toxicities.

Growing Awareness of Gastrointestinal and Genitourinary Toxicities

Increasing recognition of GI/GU toxicities associated with pelvic radiation is expected to strengthen demand for supportive care and improve identification and management of radiation-induced complications. Late toxicities may develop months or even years after radiotherapy and can remain underrecognized by oncology teams and other clinicians.

Increasing Adoption of Advanced Radiotherapy Techniques

Advanced radiotherapy techniques such as IMRT and SBRT are becoming increasingly dominant, while conventional modalities are declining. IMRT is currently the most widely adopted advanced form of radiotherapy in prostate cancer in the United States, with its ability to deliver higher and more conformal doses supporting its continued adoption.

Development of Cost-Effective Therapies and Preventive Strategies

The lack of approved pharmacologic therapies for radiation-induced mucositis creates a significant therapeutic gap. The development of cost-effective therapies, preventive strategies, improved reporting systems, and disease-modifying approaches is expected to provide opportunities for market growth during the forecast period.

Radiation-Induced Oral Mucositis in Prostate Cancer Competitive Landscape

The Radiation-Induced Oral Mucositis in Prostate Cancer treatment landscape remains largely supportive and symptom-driven, as there are currently no approved pharmacologic therapies specifically designed to prevent, reverse, or modify radiation-induced mucosal injury. Current management approaches include hydration, steroid enemas, antidiarrheal agents, formalin therapy, corticosteroids, 5-aminosalicylic acid agents such as mesalamine, sucralfate, short-chain fatty acid enemas, and endoscopic or procedural interventions such as argon plasma coagulation (APC). Hyperbaric oxygen therapy may also be used for chronic and refractory disease.

The emerging landscape remains narrow, with only a limited number of programs pursuing localized or disease-modifying approaches. LP-10 and 3-D Matrix represent the most clinically advanced efforts, targeting chronic bladder and rectal mucosal injury, respectively, while other programs remain in earlier stages of development.

LP-10, developed by Lipella Pharmaceuticals, is an investigational liposomal formulation of tacrolimus designed for intravesical administration. It is being developed for hemorrhagic cystitis, a condition associated with pelvic radiation or certain chemotherapies. LP-10 has demonstrated preliminary safety and efficacy in Phase IIa clinical trials and has received FDA Orphan Drug Designation for moderate to severe hemorrhagic cystitis.

Other emerging programs include HT-02, being developed by HTnB in collaboration with US federal agencies for gastrointestinal acute radiation syndrome, and RDD-2007 from RDD Pharma, which remains in early preclinical development.

Discover more about therapies set to grab major Radiation-Induced Oral Mucositis in Prostate Cancer market share @ Radiation-Induced Oral Mucositis in Prostate Cancer Treatment Landscape

Recent Developments in the Radiation-Induced Oral Mucositis in Prostate Cancer Market

• LP-10, developed by Lipella Pharmaceuticals, has demonstrated preliminary safety and efficacy in Phase IIa clinical trials, with reductions in hematuria and improvements in urinary symptoms.

• LP-10 has received FDA Orphan Drug Designation for moderate to severe hemorrhagic cystitis and is currently being evaluated in Phase II clinical trials.

• RepoCeuticals is developing a topical melatonin therapy in Phase I for radiation cystitis/proctitis.

• 3-D Matrix represents one of the most clinically advanced emerging approaches, targeting chronic rectal mucosal injury.

• HTnB is developing HT-02 in collaboration with NIAID, NIH, and AFRRI for gastrointestinal acute radiation syndrome, with current work focused on preclinical safety, efficacy, and survival outcomes.

• RDD-2007, developed by RDD Pharma, is in early preclinical development, reflecting the nascent state of innovation in radiation-induced mucositis.

What is Radiation-Induced Oral Mucositis in Prostate Cancer?

Radiation-induced toxicities form a spectrum of mucosal and organ injury following radiotherapy, particularly in pelvic cancers. It may begin with mucositis, an inflammatory response of the oral and gastrointestinal mucosa that is painful but usually temporary. Following pelvic radiation, patients may develop radiation proctitis, which can cause diarrhea, urgency, and bleeding in acute cases and may progress to chronic complications such as strictures and fistulas.

Radiation-associated inflammation may also affect the bladder, resulting in radiation cystitis and urinary symptoms, or the colon, resulting in radiation colitis. These complications can develop months to years following treatment and may range from acute to chronic disease.

Risk factors for radiation-induced mucositis include radiation dose, treatment area, and delivery method. Doses below 45 Gy are associated with minimal long-term effects, while doses between 45–70 Gy increase complications and doses above 70 Gy can cause severe and lasting tissue damage.

Diagnosis may involve blood and stool tests to identify infection or bleeding, endoscopic procedures such as flexible sigmoidoscopy or colonoscopy with biopsy to assess intestinal injury, as well as STI testing, urinalysis, and cystoscopy to evaluate urinary tract involvement.

Radiation-Induced Oral Mucositis in Prostate Cancer Epidemiology Segmentation

The Radiation-Induced Oral Mucositis in Prostate Cancer epidemiology section provides insights into the historical and current patient burden and forecasted trends across the seven major markets. The report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Radiotherapy Utilization in Prostate Cancer

• Radiotherapy Modalities in Prostate Cancer

• Radiation-Induced Mucositis in Prostate Cancer among Radiotherapy Modalities

• Patient Burden Assessment

Scope of the Radiation-Induced Oral Mucositis in Prostate Cancer Market Report

• Therapeutic Assessment: Current supportive treatments and emerging therapies for Radiation-Induced Oral Mucositis in Prostate Cancer

• Radiation-Induced Oral Mucositis in Prostate Cancer Market Dynamics: Key market forecast assumptions, pricing trends, therapy uptake, market outlook, and patient burden

• Key Companies: Lipella Pharmaceuticals and others

• Key Therapies: LP-10 and others

• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, KOL Views, and Market Assessment

• Unmet Needs: Therapeutic gaps, limitations in prevention, real-world understanding of mucositis risk, and the need to predict and prevent radiation-induced mucositis in high-risk patients

• Market Access and Reimbursement: Assessment of reimbursement, pricing, and treatment accessibility across the 7MM

To know more about Radiation-Induced Oral Mucositis in Prostate Cancer companies working in the treatment market, visit @ Radiation-Induced Oral Mucositis in Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

• Radiation Induced Oral Mucositis in Prostate Cancer Market Report Introduction

• Executive Summary for Radiation Induced Oral Mucositis in Prostate Cancer

• Competitive Intelligence Analysis for Radiation Induced Oral Mucositis in Prostate Cancer

• Radiation Induced Oral Mucositis in Prostate Cancer Market Overview at a Glance

• Radiation Induced Oral Mucositis in Prostate Cancer Background and Overview

• Signs and Symptoms

• Pathophysiology

• Risk Factors

• Diagnosis

• Patient Journey

• Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology and Patient Population

• Country-Specific Patient Population of Radiation Induced Oral Mucositis in Prostate Cancer

• Radiation Induced Oral Mucositis in Prostate Cancer Current Treatment and Medical Practices

• Radiation Induced Oral Mucositis in Prostate Cancer Unmet Needs

• Radiation Induced Oral Mucositis in Prostate Cancer Emerging Therapies

• Radiation Induced Oral Mucositis in Prostate Cancer Market Outlook

• Country-Wise Radiation Induced Oral Mucositis in Prostate Cancer Market Analysis (2022–2036)

• Radiation Induced Oral Mucositis in Prostate Cancer Market Access and Reimbursement of Therapies

• Radiation Induced Oral Mucositis in Prostate Cancer Market Drivers

• Radiation Induced Oral Mucositis in Prostate Cancer Market Barriers

• Radiation Induced Oral Mucositis in Prostate Cancer Appendix

• Radiation Induced Oral Mucositis in Prostate Cancer Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/